These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27829335)

  • 21. A rational approach towards development of amorphous solid dispersions: Experimental and computational techniques.
    Chakravarty P; Lubach JW; Hau J; Nagapudi K
    Int J Pharm; 2017 Mar; 519(1-2):44-57. PubMed ID: 28063904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of the Dependence of the Flory-Huggins Interaction Parameter on Temperature and Composition in a Drug-Polymer System.
    Potter CB; Davis MT; Albadarin AB; Walker GM
    Mol Pharm; 2018 Nov; 15(11):5327-5335. PubMed ID: 30259745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical Stability of Amorphous Solid Dispersions: a Physicochemical Perspective with Thermodynamic, Kinetic and Environmental Aspects.
    Lin X; Hu Y; Liu L; Su L; Li N; Yu J; Tang B; Yang Z
    Pharm Res; 2018 Apr; 35(6):125. PubMed ID: 29687226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Theoretical and experimental investigation of drug-polymer interaction and miscibility and its impact on drug supersaturation in aqueous medium.
    Baghel S; Cathcart H; O'Reilly NJ
    Eur J Pharm Biopharm; 2016 Oct; 107():16-31. PubMed ID: 27378287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of amorphous-amorphous phase separation in small molecular co-amorphous mixtures with SEM-EDS.
    Pajula K; Hyyryläinen J; Koistinen A; Leskinen JTT; Korhonen O
    Eur J Pharm Biopharm; 2020 May; 150():43-49. PubMed ID: 32151730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions.
    Ghebremeskel AN; Vemavarapu C; Lodaya M
    Pharm Res; 2006 Aug; 23(8):1928-36. PubMed ID: 16871443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melt extrusion with poorly soluble drugs.
    Shah S; Maddineni S; Lu J; Repka MA
    Int J Pharm; 2013 Aug; 453(1):233-52. PubMed ID: 23178213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging trends in the stabilization of amorphous drugs.
    Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
    Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mid-infrared spectroscopy as a polymer selection tool for formulating amorphous solid dispersions.
    Wegiel LA; Mauer LJ; Edgar KJ; Taylor LS
    J Pharm Pharmacol; 2014 Feb; 66(2):244-55. PubMed ID: 24433425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Application of Modeling and Prediction to the Formation and Stability of Amorphous Solid Dispersions.
    DeBoyace K; Wildfong PLD
    J Pharm Sci; 2018 Jan; 107(1):57-74. PubMed ID: 28389266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
    Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
    Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction.
    Chen Y; Wang S; Wang S; Liu C; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
    Pharm Res; 2016 Oct; 33(10):2445-58. PubMed ID: 27283830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co amorphous systems: A product development perspective.
    Chavan RB; Thipparaboina R; Kumar D; Shastri NR
    Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mechanistic investigation of an amorphous pharmaceutical and its solid dispersions, part II: molecular mobility and activation thermodynamic parameters.
    Shmeis RA; Wang Z; Krill SL
    Pharm Res; 2004 Nov; 21(11):2031-9. PubMed ID: 15587925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the carrier in the formulation of pharmaceutical solid dispersions. Part I: crystalline and semi-crystalline carriers.
    Van Duong T; Van den Mooter G
    Expert Opin Drug Deliv; 2016 Nov; 13(11):1583-1594. PubMed ID: 27321133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Assessment of Miniaturized Screening Approaches for Selection of Polymers for Amorphous Drug Stabilization.
    Banda A; Manchanda A; Zhang W; Alba GM; Nagapudi K
    J Pharm Sci; 2018 Mar; 107(3):897-908. PubMed ID: 29155235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Silico Screening for Solid Dispersions: The Trouble with Solubility Parameters and χFH.
    Turpin ER; Taresco V; Al-Hachami WA; Booth J; Treacher K; Tomasi S; Alexander C; Burley J; Laughton CA; Garnett MC
    Mol Pharm; 2018 Oct; 15(10):4654-4667. PubMed ID: 30142269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.